abstract: HYPOTHESIS: There is an increased operative risk in @entity1 with a history of @entity1095 ( @entity1095 ) who undergo @entity453 ( @entity453 ). There are also outcome differences associated with these @entity1 . DESIGN: A study from a 10-year hospitalization cohort with prospective data collection. SETTING: Multiple hospitals in the Greater Cincinnati area with 1 surgical group of cardiac surgeons. @entity1 : Cases were @entity453 @entity1 with @entity1095 , which was defined as having a history of type 1 @entity16 , prior vascular surgery, or current @entity455 (n = 1561). Controls were @entity453 @entity1 without @entity1095 (n = 6328). INTERVENTIONS: The study examined 42 potential confounding risk factors and 16 outcome variables. RESULTS: Twenty-nine potential risk factors were found to be significantly different between @entity453 @entity1 with and without @entity1095 . Twenty-six confounding risk factors were correlated with 3 factors. Logistic regression analysis showed that even after controlling for sex, significant associative disorders, and other procedures, @entity453 @entity1 with @entity1095 still experienced more @entity943 requiring treatment (odds ratio [OR], 1.7; 95% confidence interval [CI], 1.03-1.33; P = .01), @entity16 (OR, 1.7; 95% CI, 1.43-2.07; P<.001), @entity358 (OR, 1.4; 95% CI, 1.23-1.62; P<.001), low output (OR, 1.3; 95% CI, 1.09-1.45; P = .001), and @entity3816 (OR, 1.39; 95% CI, 1.06-1.83; P = .02). CONCLUSIONS: @entity1 with a @entity1095 history undergoing @entity453 had more coexistent risk factors. These @entity1 also exhibited higher rates of @entity149 .

title: XXXX and outcomes following coronary artery bypass graft surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PARTICIPANTS']

entities_list: @entity1095 :: ('MESH:D016491', 'Disease') :: ['PVD', 'peripheral vascular disease']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular disease']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological complications', 'neurologic injury']

entities_list: @entity149 :: ('MESH:D002493', 'Disease') :: ['cardiac, systemic, renal, neurologic, and pulmonary complications']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary complications']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery bypass grafting', 'CABG']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmias']

entities_list: @entity3816 :: ('MESH:D007431', 'Disease') :: ['intraoperative complications']

answer: @entity1095 :: (MESH:D016491,Disease) :: ['Peripheral vascular disease']


abstract: PURPOSE: To determine the clinical relevance of @entity993 ( @entity13525 ) in @entity1582 ( @entity1582 ), we examined the relationship between @entity993 ( @entity13525 ) expression at diagnosis and clinical as well as laboratory parameters, including response to chemotherapy and overall survival in 74 previously untreated @entity1 with @entity1582 . EXPERIMENTAL DESIGN: Expression of @entity993 ( @entity13525 ) was assessed by immunohistochemistry on @entity406 -fixed, @entity982 -embedded bone marrow biopsies. @entity993 ( @entity13525 ) expression was classified as low (</=5% @entity993 ( @entity13525 )-positive @entity1582 cells) or high (>5% @entity993 ( @entity13525 )-positive @entity1582 cells). RESULTS: Low @entity993 ( @entity13525 ) expression was observed in 23 (31%) @entity1 . The response rate to standard dose chemotherapy (including @entity1891 , @entity632 , and @entity619 induction before high-dose chemotherapy) was 70%, with no significant difference between @entity1 with low or high @entity993 ( @entity13525 ) expression (83 versus 65%; P = 0.1). Kaplan-Meier analysis of all 74 @entity1 revealed that @entity1 with low @entity993 ( @entity13525 ) expression had a significantly shorter overall survival (median, 3.7 years versus 4.7 years; P = 0.03) than those with high @entity993 ( @entity13525 ) expression. @entity1 with high @entity993 ( @entity13525 ) expression receiving high-dose chemotherapy experienced prolonged overall survival as compared with those with low @entity993 ( @entity13525 ) expression (median not yet reached versus 2.9 years; P = 0.008). By multivariate Cox regression analyses, low @entity993 ( @entity13525 )(P = 0.03), deletion of chromosome 13q14 (P = 0.02), and @entity2262 (P = 0.01) were identified as independent adverse prognostic factors for overall survival. According to the number of independent unfavorable prognostic factors present in each @entity1 , low-risk, intermediate-risk, and high-risk @entity1 with different overall survival times were defined (median overall survival, 6.3 versus 4.2 versus 1.8 years; P < 0.001). CONCLUSIONS: Low @entity993 ( @entity13525 ) expression is an independent adverse prognostic factor in @entity1 with @entity1582 . The proposed risk score might be useful for risk-adapted treatment in the future.

title: Low XXXX expression is an independent adverse prognostic factor in @entity1 with @entity1582 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity2262 :: ('567', 'Gene') :: ['beta(2)-microglobulin']

entities_list: @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin']

entities_list: @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'myeloma', 'MM']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin']

entities_list: @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine']

answer: @entity13525 :: (1027,Gene) :: ['p27Kip1']


abstract: UNASSIGNED: @entity9576 ( @entity9576 ) is a sporadic @entity179 clinically characterized by cerebellar signs, @entity304 , and @entity5433 . Pathologically, @entity9576 is an a-synucleinopathy affecting striatonigral and olivopontocerebellar systems, while neocortical and limbic involvement is usually minimal. In this study, we describe four @entity1 with @entity9576 with clinical features consistent with @entity4943 ( @entity4943 ), including two with corticobasal syndrome, one with progressive @entity17787 , and one with behavioral variant @entity4943 . None had @entity5433 . All had frontotemporal @entity194 and severe limbic a-synuclein neuronal pathology. The neuronal inclusions were heterogeneous, but included @entity8637 body-like inclusions. The latter were strongly associated with @entity528 in the hippocampus and amygdala. Unlike typical @entity8637 bodies, the neuronal inclusions were positive on Gallyas silver stain and negative on tau immunohistochemistry. In comparison to 34 typical @entity9576 cases, @entity9576 had significantly more neuronal inclusions in anteromedial temporal lobe and limbic structures. While uncommon, our findings suggest that @entity9576 may present clinically and pathologically as a @entity747 ( @entity747 ). We suggest that this may represent a novel subtype of @entity747 associated with a-synuclein ( @entity747 -synuclein).

title: Atypical multiple system XXXX is a new subtype of @entity747 : @entity747 associated with a-synuclein.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity304 :: ('MESH:D010302', 'Disease') :: ['parkinsonism']

entities_list: @entity17787 :: ('MESH:D057178', 'Disease') :: ['non-fluent aphasia']

entities_list: @entity9576 :: ('MESH:D019578', 'Disease') :: ['MSA', 'Multiple system atrophy', 'atypical MSA']

entities_list: @entity747 :: ('MESH:D057174', 'Disease') :: ['frontotemporal lobar degeneration', 'FTLD']

entities_list: @entity179 :: ('MESH:D019636', 'Disease') :: ['neurodegenerative disease']

entities_list: @entity4943 :: ('MESH:D057180', 'Disease') :: ['FTD', 'frontotemporal dementia']

entities_list: @entity5433 :: ('MESH:C563939', 'Disease') :: ['autonomic dysfunction']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal loss']

answer: @entity194 :: (MESH:D001284,Disease) :: ['atrophy']


abstract: Cure for @entity1124 is restricted to resectable @entity5 , but survival after surgery is still poor. Despite apparently curative resection, these @entity5 rapidly recur. Thus, the present pathologic examination should be enriched by sensitive methods to detect minimal @entity66 . In a prospective setting we studied the frequency of minimal @entity66 after curative resection by routine histopathology, immunohistology, and polymerase chain reaction (PCR) for mutated @entity984 . Furthermore, the prognostic implication of detecting of @entity4145 was determined. Prospectively, @entity5 tissue and corresponding paraaortic lymph nodes were obtained from 78 @entity1 , who underwent surgery for pancreatic @entity135 between 1999 and 2001. Sixty-nine of 78 cases were diagnosed for @entity420 (study group), whereas nine cases were diagnosed for benign @entity788 (control group). Paraaortic lymph nodes were examined in step sections by routine histopathology ( @entity1710 and @entity1711 ) and immunohistology using a pan-cytokeratin antibody. DNA of the @entity5 and corresponding paraaortic lymph nodes were analyzed by PCR-based assays with respect to mutated @entity984 in codon 12. The recurrence-free survival and overall survival were correlated with the results of the latter methods. In 3 of 69 @entity1 @entity5 cells were detected in paraaortic lymph nodes by routine histopathology and in 5 of 69 @entity1 by immunohistology. @entity984 mutations were detected in 42 of 69 ductal @entity420 (61%), whereas 12 (17%) were positive in paraaortic lymph nodes. All of the latter @entity1 had recurrence after surgery and a significant poorer survival than those without mutated @entity984 . Furthermore, paraaortic lymph nodes diagnosed for @entity984 mutation were independent prognostic markers in multivariate analysis. In the control group @entity984 mutations were detected in one @entity652 of @entity1829 but not in paraaortic lymph nodes. Tumor cell DNA can be detected more sensitively by the described PCR method than with @entity1710 and @entity1711 or immunohistologic staining, leading to a higher sensitivity for detection of micrometastases. The described PCR method clearly determines subgroups of @entity1 after curative resection with early recurrence and poor survival and could therefore enrich the pathologic examination.

title: Prognostic implications of routine, immunohistochemical, and molecular staging in resectable XXXX .

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head tumors']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic tumors']

entities_list: @entity1124 :: ('MESH:D021441', 'Disease') :: ['ductal adenocarcinoma of the pancreas']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'primary tumor', 'tumors']

entities_list: @entity1710 :: ('MESH:D006416', 'Chemical') :: ['hematoxylin']

entities_list: @entity1829 :: ('MESH:D010211', 'Disease') :: ["Vater's papilla"]

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinomas', 'ductal adenocarcinoma']

answer: @entity788 :: (MESH:D010190,Disease) :: ['pancreatic adenocarcinoma']


abstract: BACKGROUND: The @entity9275 dehydrogenase ( @entity818 / @entity14051 ) genes are metabolic enzymes, which are frequently mutated in @entity3052 ( @entity3052 ). The enzymes acquire neomorphic enzymatic activity when they mutated. METHODS: We have investigated the frequency and outcome of the acquired @entity818 / @entity14051 mutations and the @entity818 SNP @entity65497 ( @entity65498 ) in 189 unselected de novo @entity3052 @entity1 by polymerase chain reaction amplification followed by direct sequencing. The survival are presented in Kaplan Meier curves with log rank test. Multivariable survival analysis was conducted using Cox regression method, taking age, risk group, treatment, @entity8725 mutations and @entity818 SNP105 genotype into account. RESULTS: Overall, @entity8725 mutations were found in 41/187 (21.7%) of the @entity3052 @entity1 . @entity818 codon 132 mutations were present in 7.9%, whereas @entity14051 mutations were more frequent and mutations were identified in codon 140 and 172 in a frequency of 11.1% and 2.6%, respectively. The SNP @entity65497 was present in 10.5% of the @entity1 , similar to the normal population. A significantly reduced @entity1349 ( @entity1349 ) for @entity1 carrying @entity14051 codon 140 mutation compared with @entity1 carrying wild-type @entity14051 gene (p   <   0.001) was observed in the intermediate risk @entity1 group. Neither in the entire @entity1 group nor subdivided in different risk groups, @entity818 mutations had any significance on @entity1349 compared to the wild-type @entity818 @entity1 . A significant difference in @entity1349 between the heterozygous SNP variant and the homozygous wild-type was observed in the intermediate risk @entity7801 negative @entity3052 @entity1 (p   =   0.004). CONCLUSIONS: Our results indicate that @entity3052 - @entity1 with @entity14051 mutations or the @entity818 SNP @entity65497 variant can represent a new subgroup for risk stratification and may indicate new treatment options.

title: Mutations in the isocitrate dehydrogenase 2 gene and @entity818 SNP @entity65497 have a prognostic value in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

entities_list: @entity9275 :: ('MESH:C034219', 'Chemical') :: ['isocitrate']

answer: @entity3052 :: (MESH:D015470,Disease) :: ['acute myeloid leukemia']


abstract: BACKGROUND: In @entity1 with @entity134 -dependent @entity1985 (SDNS), long-term remission (LTR) can usually be achieved with @entity205 (CSA), after alternative treatment with cytotoxic drugs or @entity7305 has failed. Nevertheless, severe SDNS recurs in some @entity1 despite CSA maintenance therapy. Few data are available on the clinical course and treatment strategies in these @entity1 . METHODS: We carried out a retrospective chart analysis of 46 @entity1 with SDNS treated with @entity870 , after failure of cytotoxic treatment with @entity786 (CPO). Median age at primary manifestation was 3.0 years (range 0.8-6.9) and median current age is 20.4 years (range 8.6-29.1). @entity1 were recruited from three centres caring for a total of 186 @entity1 with @entity134 -sensitive @entity1985 . RESULTS: In 14 of the 46 @entity1 (30%; 10 male), severe SDNS recurred again despite CSA maintenance therapy. Seven @entity1 relapsed beyond the age of 18 years. Nine of 14 @entity1 received a further course of cytotoxic treatment as first intervention: six were treated with @entity5805 (CLA) and three with CPO. Four of the CLA-treated @entity1 remained in LTR in contrast to none after CPO. Five @entity1 received levamisole after CSA: only one went into LTR, while in one other CSA could be discontinued although further relapses occurred. One further @entity1 was switched to CLA after levamisole, finally inducing LTR. Overall, six @entity1 required two or more drugs, and in four of these CSA maintenance ultimately had to be restarted. CONCLUSION: We conclude that SDNS can recur in @entity1 despite CSA maintenance therapy. Treatment strategies for this subgroup of @entity1 are complex and should be standardized to optimize long-term outcome. A subgroup of @entity1 with childhood SDNS continues to relapse into adulthood.

title: Recurrence of severe XXXX dependency in @entity205 -treated childhood idiopathic nephrotic syndrome.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity7305 :: ('MESH:D007978', 'Chemical') :: ['levamisole']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity5805 :: ('MESH:D002699', 'Chemical') :: ['chlorambucil']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid']

entities_list: @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporin A']

entities_list: @entity1985 :: ('MESH:D009404', 'Disease') :: ['nephrotic syndrome']

answer: @entity134 :: (CHEBI:35341,Chemical) :: ['steroid']


abstract: Abnormalities in dendritic spines have long been associated with @entity73 and @entity245 , whereas rapid changes in spine shape underlie synaptic plasticity. The key regulators of cytoskeletal reorganization in dendrites and spines are the Rho GTPases, which modify actin polymerization in response to synaptic signaling. Rho GTPase activity is modulated by multiple regulatory proteins, some of which have been found to associate with proteins localized to spines. Here, we show that the nonkinase @entity4621 receptor alpha1-chimerin is present in dendrites and spines, where it binds to the @entity143 receptor @entity11588 subunit in a @entity4621 -dependent manner. Alpha1-chimerin contains a GTPase activating (GAP) domain, with activity toward the Rho family member @entity5180 . Overexpression of alpha1-chimerin in cultured hippocampal neurons inhibits formation of new spines and removes existing spines. This reduction in spine density is mediated by @entity5180 inhibition, because it depends critically on the presence of a functional GAP domain. Conversely, depletion of alpha1-chimerin leads to an increase in spine density, indicating that a basal inhibition of @entity5180 maintains the number of spines at a submaximal level. The ability of alpha1-chimerin to modulate spine number requires an interaction with the @entity143 receptor, because an alpha1-chimerin mutant that binds weakly to @entity11588 fails to decrease spine density. Together, these results suggest that alpha1-chimerin is able to modulate dendritic spine morphology by binding to synaptic @entity143 receptors and locally inactivating @entity5180 .

title: The nonkinase @entity4621 receptor alpha 1-chimerin binds the XXXX receptor @entity11588 subunit and regulates dendritic spine density.

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive dysfunction']

entities_list: @entity245 :: ('MESH:D002658', 'Disease') :: ['neurodevelopmental delay']

entities_list: @entity4621 :: ('CHEBI:37532', 'Chemical') :: ['phorbol ester']

answer: @entity143 :: (CHEBI:6121,Chemical) :: ['NMDA']


abstract: The fate of octogenarians reaching @entity454 ( @entity454 ) is poorly defined, and implicit dialysis rationing may be practiced in this age group. The main objectives of this study were to analyze the characteristics of pre- @entity454 octogenarians offered dialysis or not and to identify factors influencing mortality while on dialysis, to improve prognosis assessment and decision-making. In this single-center cohort, 146 consecutive pre- @entity454 octogenarians were referred to a nephrology unit over a 12-yr period (1989 to 2000). Main outcome measures were baseline characteristics of @entity1 offered dialysis and conservative therapy and overall and 1-yr survival according to effective treatment. A therapeutic decision was made for 144 @entity1 . Octogenarians who were not proposed dialysis (n = 37) differed from those who were proposed dialysis (n = 107) mainly in terms of social isolation (43.3% versus 14.7%; P = 0.03), late nephrologic referral (51.4% versus 28.9%; P = 0.01), Karnofsky score (55 +/- 18 versus 63 +/- 20; P = 0.03), and @entity6 status (22.2% versus 6.5%, P = 0.008). Six @entity1 refused the dialysis proposal. During the 12-yr observation period, 99 @entity1 died (68.7%). Median survival was 28.9 mo (95% CI, 24 to 38) in @entity1 undergoing dialysis, compared with 8.9 mo (95% CI, 4 to 10) in @entity1 treated conservatively (P < 0.0001). In multivariable piecewise Cox analysis, independent predictors of @entity204 within 1 yr on dialysis were poor nutritional status, late referral, and functional @entity734 . Included in a survivor function, these covariates predict groups with low and high 1-yr mortality risk. Beyond 1 yr on dialysis, the only independent predictor of @entity204 was the presence of @entity1095 . It is concluded that beside a @entity1 's individual refusal, late referral, social isolation, low functional capacity, and @entity6 may have oriented medical decision toward withholding dialysis in a significant proportion of pre- @entity454 octogenarians. Although most @entity1 on dialysis experienced a substantial prolongation of life, identification of mortality predictors in this age group should improve the process of decision-making regarding the expected benefit of renal replacement therapy.

title: Octogenarians reaching XXXX : cohort study of decision-making and clinical outcomes.

entities_list: @entity1095 :: ('MESH:D016491', 'Disease') :: ['peripheral vascular disease']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['dependence']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease', 'ESRD']

answer: @entity454 :: (MESH:D007676,Disease) :: ['end-stage renal disease']


abstract: Objectives. Biologically guided radiotherapy needs an understanding of how different functional imaging techniques interact and link together. We analyse three functional imaging techniques that can be useful tools for achieving this objective. Materials and Methods. The three different imaging modalities from one selected @entity1 are ADC maps, DCE-MRI, and @entity419 PET/CT, because they are widely used and give a great amount of complementary information. We show the relationship between these three datasets and evaluate them as markers for @entity5 response or @entity519 marker. Thus, vascularization measured using DCE-MRI parameters can determine @entity5 , and ADC maps can be used for evaluating @entity5 response. Results. ADC and DCE-MRI include information from @entity419 , as @entity413 metabolism is associated with @entity519 and @entity5 cell density, although @entity419 includes more information about the @entity5 . The main disadvantage of ADC maps is the distortion, and we used only low distorted regions, and extracellular volume calculated from DCE-MRI can be considered equivalent to ADC in well-vascularized areas. Conclusion. A dataset for achieving the biologically guided radiotherapy must include a @entity5 density study and a @entity519 marker. This information can be achieved using only MRI data or only PET/CT studies or mixing both datasets.

title: Multimodality Functional Imaging in Radiation Therapy Planning: Relationships between Dynamic Contrast-Enhanced MRI, Diffusion-Weighted MRI, and XXXX PET.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour hypoxia', 'malignancy of the tumour', 'tumour']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity419 :: (MESH:D019788,Chemical) :: ['18F-FDG']


abstract: IMPORTANCE: Cerebrospinal fluid (CSF) and positron emission tomographic (PET) amyloid biomarkers have been proposed for the detection of @entity195 ( @entity195 ) pathology in living @entity1 and for the tracking of longitudinal changes, but the relation between biomarkers needs further study. OBJECTIVE: To determine the association between CSF and PET amyloid biomarkers ( @entity2915 ) and compare the cutoffs for these measures. DESIGN, SETTING, AND @entity1 : Longitudinal clinical cohort study from 2005 to 2014 including 820 @entity1 with at least 1 florbetapir @entity29786 (hereafter referred to as simply florbetapir)-PET scan and at least 1 CSF b-amyloid 1-42 (Ab1-42) sample obtained within 30 days of each other (501 @entity1 had a second PET scan after 2 years, including 150 @entity1 with CSF Ab1-42 measurements). Data were obtained from the @entity195 Neuroimaging Initiative database. MAIN OUTCOMES AND MEASURES: Four different PET scans processing pipelines from 2 different laboratories were compared. The PET cutoff values were established using a mixture-modeling approach, and different mathematical models were applied to define the association between CSF and PET amyloid measures. RESULTS: The values of the CSF Ab1-42 samples and florbetapir-PET scans showed a nonlinear association (R2   =   0.48-0.66), with the strongest association for values in the middle range. The presence of a larger dynamic range of florbetapir-PET scan values in the higher range compared with the CSF Ab1-42 plateau explained the differences in correlation with cognition (R2   =   0.36 and R2   =   0.25, respectively). The @entity2204 genotype significantly modified the association between both biomarkers. The PET cutoff values derived from an unsupervised classifier converged with previous PET cutoff values and the established CSF Ab1-42 cutoff levels. There was no association between longitudinal Ab1-42 levels and standardized uptake value ratios during follow-up. CONCLUSIONS AND RELEVANCE: The association between both biomarkers is limited to a middle range of values, is modified by the @entity2204 genotype, and is absent for longitudinal changes; 4 different approaches in 2 different platforms converge on similar pathological Ab cutoff levels; and different pipelines to process PET scans showed correlated but not identical results. Our findings suggest that both biomarkers measure different aspects of @entity195 Ab pathology.

title: Nonlinear Association Between Cerebrospinal Fluid and Florbetapir @entity29786 b-Amyloid Measures Across the Spectrum of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'PARTICIPANTS']

entities_list: @entity2915 :: ('MESH:D006948', 'Disease') :: ['cross-sectional and longitudinal measures']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's Disease", 'Alzheimer disease']

answer: @entity195 :: (MESH:D000544,Disease) :: ['Alzheimer Disease']


abstract: @entity143 receptor hypofunction has been implicated in the pathophysiology of @entity161 , and pharmacological and genetic approaches have been used to model @entity409 . We previously have described two @entity19 lines carrying point mutations in the @entity143 receptor @entity2228 binding site, @entity13429 ( @entity66293 ) and @entity13429 ( @entity66294 ), which exhibit 5- and 86-fold reductions in receptor @entity2228 affinity, respectively. @entity13429 ( @entity66293 ) animals exhibit a relatively mild phenotype compatible with a moderate reduction in @entity143 receptor function, whereas @entity13429 ( @entity66294 ) animals die shortly after birth. In this study we have characterized compound heterozygote @entity13429 ( @entity66293 / @entity66294 ) @entity19 , which are viable and exhibited biphasic @entity143 receptor @entity2228 affinities compatible with the presence of each of the two mutated alleles. @entity13429 ( @entity66293 / @entity66294 ) @entity19 exhibited a marked @entity143 receptor hypofunction revealed by deficits in hippocampal long-term potentiation, which were rescued by the @entity2228 site agonist @entity7343 , which also facilitated @entity143 synaptic currents in mutant, but not in wild-type, @entity19 . Analysis of striatal @entity1154 levels revealed an apparent dopaminergic and serotonergic @entity6392 . Behaviorally, @entity13429 ( @entity66293 / @entity66294 ) @entity19 were insensitive to acute @entity3390 pretreatment and exhibited increased @entity427 response but normal prepulse inhibition. Most strikingly, mutant @entity19 exhibited a sustained, nonhabituating @entity2915 and increased stereotyped behavior that were resistant to suppression by antipsychotics and the @entity1245 site agonist Zolpidem. They also displayed a disruption of nest building behavior and were unable to perform a cued learning paradigm in the Morris water maze. We speculate that the severity of @entity143 receptor hypofunction in these @entity19 may account for their profound behavioral phenotype and insensitivity to antipsychotics.

title: Severe impairment of @entity143 receptor function in @entity19 carrying targeted point mutations in the XXXX binding site results in drug-resistant nonhabituating @entity2915 .

entities_list: @entity2228 :: ('CHEBI:57305', 'Chemical') :: ['glycine']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['such dysfunction']

entities_list: @entity1245 :: ('MESH:D001569', 'Chemical') :: ['benzodiazepine']

entities_list: @entity2915 :: ('MESH:D006948', 'Disease') :: ['hyperactivity']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

entities_list: @entity1154 :: ('CHEBI:25375', 'Chemical') :: ['monoamine']

entities_list: @entity6392 :: ('MESH:D000308', 'Disease') :: ['hyperfunction']

entities_list: @entity3390 :: ('MESH:D016291', 'Chemical') :: ['dizocilpine']

answer: @entity2228 :: (CHEBI:57305,Chemical) :: ['glycine']


abstract: BACKGROUND _ AIMS: Hyponatraemia in @entity82 is associated with @entity73 and poor health-related quality of life (HRQOL). However, the benefit of hyponatraemia correction is unclear. The aim of this study was to evaluate the effect of @entity12182 on serum @entity1372 (Na), cognition, HRQOL, companion burden, and brain MRI (volumetrics, spectroscopy, and diffusion tensor imaging) in cirrhotics with hyponatraemia. METHODS: Cirrhotics with Na <130mEq/L were included for a four-week trial. At screening, @entity1 underwent cognitive and HRQOL testing, serum/urine chemistries and companion burden assessment. @entity1 then underwent fluid restriction and diuretic withdrawal for two weeks after which cognitive tests were repeated. If Na was still <130mEq/L, brain magnetic resonance imaging (MRI) was performed and @entity12182 was initiated for 14days with frequent clinical/laboratory monitoring. After 14days of @entity12182 , all tests were repeated. Comparisons were made between screen, pre-and post-drug periods Na, urine/serum laboratories, cognition, HRQOL and companion burden. RESULTS: 24 cirrhotics were enrolled; seven normalized Na without @entity12182 with improvement in cognition. The remaining 17 received @entity12182 of which 14 completed the study over 13  2days (age 58  6years, MELD 17, 55% @entity3531 , median 26mg/day of @entity12182 ). Serum Na and urine free water clearance increased with @entity12182 without changes in mental status or liver function. Cognitive function, HRQOL and companion burden only improved in these 14 @entity1 after @entity12182 , along with reduced total brain and white matter volume, increase in @entity1877 on magnetic resonance spectroscopy, and @entity2657 . CONCLUSIONS: Short-term @entity12182 therapy is well tolerated in @entity82 . Hyponatraemia correction is associated with cognitive, HRQOL, brain MRI and companion burden improvement.

title: Correction of hyponatraemia improves cognition, quality of life, and brain oedema in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis']

entities_list: @entity2657 :: ('MESH:D001929', 'Disease') :: ['reduced cytotoxic oedema']

entities_list: @entity12182 :: ('MESH:C116664', 'Chemical') :: ['tolvaptan']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impaired cognition']

answer: @entity82 :: (MESH:D005355,Disease) :: ['cirrhosis']


abstract: 1. The effects of treatment with @entity14808 ( @entity14808 ), an irreversible beta-adrenoceptor antagonist, for 30 min on the contractile responses of the @entity35 left atria and portal vein have been determined. 2. On the electrically driven @entity35 left atria, @entity14808 at 10(-5) M followed by a 60-min wash-out caused parallel rightward shifts of the @entity3044 response curves with no reduction in the maximal response to @entity3044 . 3. Treatment of the atria with @entity14808 at 3 x 10(-5) M caused non-parallel rightward shifts of @entity3044 response curves with a reduction in the maximum response to @entity3044 . The KA (dissociation constant) for @entity3044 at beta 1-adrenoceptors was 7.3 x 10(-7) M. Calculation of receptor occupancy demonstrated that in order to produce a maximal response of the @entity35 left atria, @entity3044 had to occupy 12% of the beta 1-adrenoceptors. 4. Treatment of the atria with higher concentrations of @entity14808 (greater than or equal to 6 x 10(-5) M) caused a non-specific action, the reduction of the response to electrical stimulation. 5. On the @entity35 portal vein, @entity14808 at 3 x 10(-7)-3 x 10(-6) M followed by a 45-min wash-out had no effect on the spontaneous contractile activity, caused non-parallel rightward shifts of @entity3044 response curves with a @entity308 of the @entity3044 maximum responses. Using data derived from experiments with 3 x 10(-7), 10(-6) and 3 x 10(-6) M @entity14808 , the KA for @entity3044 at @entity10341 was 6.4, 3.7 and 7.7 x 10(-7) M and the calculated receptor occupancy was that in order to produce a maximal response of the @entity35 portal vein, @entity3044 had to occupy 14, 21 and 12%, respectively of the beta 2-adrenoceptors. 6. The present study with the @entity35 left atria and portal vein has shown that it is possible to determine treatments with @entity14808 that produce no non-specific actions and consequently @entity14808 may be used as an experimental tool in KA and receptor occupancy determinations in these tissues.

title: Effects of XXXX ( @entity14808 ), an irreversible beta-adrenoceptor antagonist, on the @entity35 isolated left atria and portal vein.

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity14808 :: ('MESH:C045331', 'Chemical') :: ['bromoacetylalprenololmenthane', 'BAAM']

entities_list: @entity3044 :: ('MESH:D007545', 'Chemical') :: ['isoprenaline']

answer: @entity14808 :: (MESH:C045331,Chemical) :: ['bromoacetylalprenololmenthane']


abstract: BACKGROUND: Eosinophil infiltration is a characteristic feature of @entity32 . @entity56 responses are associated with local activation of the coagulation pathway and accumulation of fibrin. OBJECTIVE: We tested whether protein C and @entity10855 ( @entity10855 ), which are endogenous anti-inflammatory coagulation inhibitors, affect eosinophil function. METHODS: Eosinophils were from venous blood of healthy donors. Cell @entity4222 and apoptosis were studied by using micropore filter assays and fluorometry, respectively. Receptor expression was investigated by means of RT-PCR and @entity214 -PAGE of immunoprecipitated protein. RESULTS: Protein C and @entity10855 had no significant chemotactic effects on eosinophils. Eosinophils pretreated with protein C or @entity10855 showed significantly reduced @entity4222 toward chemoattractants. No effect of either protein C preparation was seen in eosinophil apoptosis assays. The inhibiting effect on @entity4222 was reversed by an antibody against the @entity25698 ( @entity25698 ). Synthesis of @entity25698 by eosinophils is suggested by demonstration of receptor mRNA expression and detection of metabolically labeled receptor protein. CONCLUSIONS: Data suggest that an @entity25698 is expressed by eosinophils whose activation with protein C or @entity10855 arrests directed @entity4222 . Protein C-affected eosinophil chemotaxis is a novel thrombin-independent component of the protein C pathway.

title: XXXX -dependent inhibition of human eosinophil chemotaxis by protein C.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['allergic inflammation']

entities_list: @entity4222 :: ('MESH:D014085', 'Disease') :: ['migration']

entities_list: @entity10855 :: ('MESH:D020016', 'Disease') :: ['APC', 'activated protein C']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['Allergic']

entities_list: @entity25698 :: ('10544', 'Gene') :: ['EPCR', 'endothelial protein C receptor']

answer: @entity25698 :: (10544,Gene) :: ['Endothelial protein C receptor']


abstract: UNASSIGNED: e11044 Background: Reports from low and middle income countries, including Arab countries ( El Saghir NS , et al. Int J Surg. 2007 Aug;5(4):225-33) show an increased proportion of @entity1 below 50y with @entity0 , advanced stages at presentation (60-80%), high mastectomy rates (60-80%) and poor survival. Such data provided background for widespread awareness campaigns led by local practicing physicians and health authorities, and helped by a concerned international community. METHODS: We reviewed the records of all @entity1 treated in the general oncology practice at the American University of Beirut Medical Center (AUBMC) between1997-2007. @entity1 (pts) were staged according to AJCC 7th edition. Data was entered and analyzed using PASW. Disease-free survival (DFS) was calculated from time of diagnosis till time of distant recurrence. Overall survival (OS) was calculated from time of diagnosis till time of last follow-up or @entity204 . The study was approved by IRB of the AUB. Survival analysis was done according to Kaplan-Meier method. RESULTS: Of a total of 386 @entity0 pts, 83 had Stage I, 161 Stage II, 106 Stage III and 36 Stage IV. Early stages (I and II) constituted 63.2% (244/386 pts), while advanced stages (III and IV) constituted 36.8%. Clinical characteristics, treatment and survival data are presented in the table. Data on stage III @entity1 was presented at SABCS (El-Saghir NS, et al. SABCS 2010, abstract P1-11-17). Number of @entity1 with stage IV is too small to analyze. CONCLUSIONS: Two-thirds of @entity1 seen had early stages at presentation rather than late ones as was reported in earlier years. Early diagnosis and multimodality therapy resulted in excellent long-term survival. Awareness campaigns and early detection have changed the stages at presentation and outcome of @entity0 as evident from this study from Lebanon. [Table: see text].

title: Changing characteristics and improved outcome of early XXXX in low- and middle-income countries.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: OBJECTIVE: To further resolve the clinical equipoise on the choice of chemical sphincterotomy agent for early symptomatic relief of anal fissure by comparing the effectiveness of 2% Diltiazem gel with 0.2% @entity1242 . METHODS: The randomized clinical trial was conducted at Aga Khan University Hospital, Karachi, from February 1, to July 30, 2008, and comprised 60 adult @entity1 with anal fissure who were equally randomised to either Diltiazem or @entity1242 after taking informed consent. The creams were applied locally; the former twice daily, and the latter three times a day for a period of two weeks. The rest of the treatment was standard. @entity1 were followed up in clinic by the principal investigator at two weeks for primary outcome i.e. self-reported symptomatic relief on Visual Analogue Scale, and secondary outcomes i.e. side effects and the overall cost of treatment. RESULTS: Of the total, 31 (52%) @entity1 were males and the overall mean age was 37 +/- 11 years. @entity1 , who used Diltiazem reported more symptomatic relief than @entity1242 (p < 0.01). Side effects were found more in @entity1242 than Diltiazem (p < 0.01), and most common side effect in the former group was @entity10 in 12 (40%) @entity1 . Cost of the treatment was not significantly different between both treatment arms (p < 0.28). CONCLUSION: Chemical sphincterotomy with topical 2% Diltiazem gel is an effective first-line treatment for early symptomatic relief of anal fissures, owing to negligible side effects.

title: Diltiazem vs. XXXX for symptomatic relief in anal fissure: a randomised clnical study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Patients']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

entities_list: @entity1242 :: ('MESH:D005996', 'Chemical') :: ['Glyceryl TriNitrate']

answer: @entity1242 :: (MESH:D005996,Chemical) :: ['glyceryl tri-nitrate']


abstract: OBJECTIVE: The objectives of this study were to introduce the classification of osteochondroma of the mandibular condyle based on computed tomographic images and to present our treatment experiences. MATERIALS AND METHODS: From January 2002 and December 2012, a total of 61 @entity1 with @entity705 were treated in our division. Both clinical and radiologic aspects were reviewed. The average follow-up period was 24.3 months with a range of 6 to 120 months. RESULTS: Two types of @entity705 were presented: type 1 (protruding expansion) in 50 @entity1 (82.0%) and type 2 (globular expansion) in 11 @entity1 (18.0%). @entity705 presented 5 forms: anterior/anteromedial (58%), posterior/posteromedial (6%), medial (16%), lateral (6%), and gigantic (14%). Local resection was performed on @entity1 with @entity705 . Subtotal condylectomy/total condylectomy using costochondral graft reconstruction with/without orthognathic surgeries was performed on @entity1 with @entity705 . During the follow-up period, @entity5 reformation, condyle absorption, and new deformity were not detected. The @entity1 almost reattained facial symmetry. CONCLUSIONS: Preoperative classification based on computed tomographic images will help surgeons to choose the suitable surgical procedure to treat the @entity705 .

title: XXXX of the mandibular condyle: a classification system based on computed tomographic appearances.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity705 :: ('MESH:D015831', 'Disease') :: ['type 2 condylar osteochondroma', 'condylar osteochondroma', 'type 1 condylar osteochondroma', 'Type 1 condylar osteochondroma']

answer: @entity705 :: (MESH:D015831,Disease) :: ['Osteochondroma']


abstract: OBJECTIVE: Integrative oncology incorporates complementary medicine (CM) therapies in @entity1 with @entity5 . We explored the impact of an integrative oncology therapeutic regimen on quality-of-life (QOL) outcomes in @entity1 with gynecological @entity5 undergoing chemotherapy. @entity1 AND METHODS: A prospective preference study examined @entity1 referred by oncology health care practitioners (HCPs) to an integrative physician (IP) consultation and CM treatments. QOL and chemotherapy-related @entity137 were evaluated using the Edmonton Symptom Assessment Scale (ESAS) and Measure Yourself Concerns and Wellbeing (MYCAW) questionnaire, at baseline and at a 6-12-week follow-up assessment. @entity15929 ( @entity15929 ) program was defined as >= 4 CM treatments, with  <=30  days between each session. RESULTS: Of 128 @entity1 referred by their HCP, 102 underwent IP consultation and subsequent CM treatments. The main concerns expressed by @entity1 were @entity1295 (79.8  %), @entity344 (64.6  %), @entity158 and @entity16 (54.5  %), and emotional distress (45.5  %). @entity1 in both @entity15929 (n   =   68) and non- @entity15929 (n   =   28) groups shared similar demographic, treatment, and @entity5 -related characteristics. ESAS @entity1295 scores improved by a mean of 1.97 points in the @entity15929 group on a scale of 0-10 and worsened by a mean of 0.27 points in the non- @entity15929 group (p   =   0.033). In the @entity15929 group, MYCAW scores improved significantly (p   <   0.0001) for each of the leading concerns as well as for well-being, a finding which was not apparent in the non- @entity15929 group. CONCLUSIONS: An IP-guided CM treatment regimen provided to @entity1 with gynecological @entity5 during chemotherapy may reduce @entity5 and improve other QOL outcomes.

title: Quality-of-life outcomes in XXXX with @entity5 referred to integrative oncology treatment during chemotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'cancer-related fatigue']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy']

entities_list: @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal symptoms']

entities_list: @entity15929 :: ('MESH:C565771', 'Disease') :: ['Adherence to the integrative care', 'AIC']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: Platelet-derived growth factor (PDGF) is a potent stimulant of smooth muscle cell migration and proliferation in culture. To test the role of PDGF in the accumulation of smooth muscle cells in vivo, we evaluated @entity6970 -/- @entity19 that develop complex lesions of @entity731 . Fetal liver cells from @entity1967 -deficient embryos were used to replace the circulating cells of lethally irradiated @entity6970 -/- @entity19 . One month after transplant, all monocytes in @entity1967 -/- chimeras are of donor origin (lack PDGF), and no PDGF-BB is detected in circulating platelets, primary sources of PDGF in lesions. Although lesion volumes are comparable in the @entity1967 +/+ and -/- chimeras at 35 weeks, lesions in @entity1967 -/- chimeras contain mostly macrophages, appear less mature, and have a reduced frequency of fibrous cap formation as compared with @entity1967 +/+ chimeras. However, after 45 weeks, smooth muscle cell accumulation in fibrous caps is indistinguishable in the two groups. Comparison of elicited peritoneal macrophages by RNase protection assay shows an altered cytokine and cytokine receptor profile in @entity1967 -/- chimeras. @entity6970 -/- @entity19 were also treated for up to 50 weeks with a PDGF receptor antagonist that blocks all three PDGF receptor dimers. Blockade of the PDGF receptors similarly delays, but does not prevent, accumulation of smooth muscle and fibrous cap formation. Thus, elimination of @entity1967 from circulating cells or blockade of PDGF receptors does not appear sufficient to prevent smooth muscle accumulation in @entity1442 of @entity731 .

title: Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in XXXX null @entity19 .

entities_list: @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced lesions']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

answer: @entity6970 :: (11816(Tax:10090),Gene) :: ['ApoE']


abstract: BACKGROUND: Harvest of more than one @entity2280 + stem cell transplant has become the standard, to ensure the option for a second autologous transplantation in @entity1 with relapsed or progressive @entity1582 ( @entity1582 ). Additional administration of the @entity436 inhibitor plerixafor has been shown to increase the efficiency of @entity2280 + stem cell harvest. However, the algorithm when to apply plerixafor is still under debate. STUDY DESIGN AND METHODS: In this retrospective study, 46 @entity1582 @entity1 were categorized into four groups according to their @entity2280 + stem cell count in peripheral blood (PB) and mobilization with or without plerixafor: Group A comprised poor mobilizers with @entity2280 + cell counts of fewer than 20       10(6) /L in PB. Group B included inadequate mobilizers with @entity2280 + cell counts of 20       10(6) /L or more in PB and a low @entity2280 + stem cell yield in the first leukapheresis session. @entity1 receiving plerixafor preemptively (Group A1) and as a rescue strategy (Group B1) were compared to @entity1 continuing stem cell collection with granulocyte-colony-stimulating factor alone (Groups A2 and B2). RESULTS: In both, the preemptive and the rescue settings, plerixafor enhanced the @entity2280 + stem cell yield significantly. Poor mobilization and administration of plerixafor was not associated with delayed engraftment. CONCLUSION: Our data demonstrate that administration of plerixafor is safe and effective and facilitates a significantly higher @entity2280 + stem cell harvest. Based on the presented data, we propose an algorithm for the use of plerixafor for @entity2280 + stem cell mobilization and harvesting in poor mobilizing @entity1582 @entity1 .

title: Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing XXXX with @entity1582 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'myeloma', 'MM']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: To explore the risk factors of portal hypertensive gastropathy (PHG) in @entity1 with @entity1956 associated @entity82 and establish a Logistic regression model of noninvasive prediction. METHODS: The clinical data of 234 hospitalized @entity1 with @entity1956 associated @entity82 from March 2012 to March 2014 were analyzed retrospectively. The dependent variable was the occurrence of PHG while the independent variables were screened by binary Logistic analysis. Multivariate Logistic regression was used for further analysis of significant noninvasive independent variables. Logistic regression model was established and odds ratio was calculated for each factor. The accuracy, sensitivity and specificity of model were evaluated by the curve of receiver operating characteristic (ROC). RESULTS: According to univariate Logistic regression, the risk factors included @entity409 , @entity2313 ( @entity2313 ), @entity648 ( @entity1906 ), prothrombin time (PT), platelet (PLT), white blood cell (WBC), portal vein diameter, spleen index, splenic vein diameter, diameter ratio, PLT to spleen volume ratio, esophageal varices (EV) and @entity2312 ( @entity2312 ). Multivariate analysis showed that @entity409 (X1), @entity1906 (X2), PLT (X3) and splenic vein diameter (X4) were the major occurring factors for PHG. The established regression model was Logit P = -2.667 + 2.186X1 - 2.167X2 + 0.725X3 + 0.976X4. The accuracy of model for PHG was 79.1% with a sensitivity of 77.2% and a specificity of 80.8%. CONCLUSION: @entity409 , @entity1906 , PLT and splenic vein diameter are risk factors for PHG and the noninvasive predicted Logistic regression model was Logit P = -2.667 + 2.186X1 - 2.167X2 + 0.725X3 + 0.976X4.

title: [Logistic regression model of noninvasive prediction for portal hypertensive gastropathy in @entity1 with XXXX associated @entity82 ].

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['cirrhosis']

entities_list: @entity1956 :: ('MESH:D006509', 'Disease') :: ['hepatitis B']

entities_list: @entity648 :: ('MESH:D001663', 'Chemical') :: ['bilirubin']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['hepatic dysfunction', 'Hepatic dysfunction']

entities_list: @entity2312 :: ('MESH:D004932', 'Disease') :: ['GV', 'gastric varices']

answer: @entity1956 :: (MESH:D006509,Disease) :: ['hepatitis B']


abstract: BACKGROUND/PURPOSE: Portoenterostomy is the procedure of choice in @entity1 with @entity2876 . The authors analyzed the long-term survival rate and complications of the procedure in @entity1 operated on at The University of Hong Kong Medical Centre between 1979 and 2000. METHODS: Seventy-seven consecutive @entity1 were analyzed by retrospective chart review. The @entity1 were divided into groups according to postoperative bile flow, decade of operation, and age at operation. The data were analyzed statistically. RESULTS: The overall actuarial transplant-free survival rate was 68% at 10 years after operation. For @entity1 with poor, partial, and good postoperative bile flow, transplant-free survival rate was 0%, 22%, and 96%, respectively (P <.001). Age and decade of operation were not significant risk factors. Esophageal variceal @entity548 occurred in 13 @entity1 and was a prognostic indicator for @entity3851 (P =.044); the poor prognosis of @entity1 with variceal @entity548 , however, was related to poor or partial initial bile drainage. CONCLUSIONS: The postoperative serum @entity648 level is the most important predictor of long-term survival in @entity1 with portoenterostomy for @entity2876 . @entity548 is not an absolute indication for urgent liver transplantation in @entity1 with good bile drainage.

title: Portoenterostomy for @entity2876 : Long-term survival and prognosis after esophageal variceal XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['Esophageal hemorrhage', 'bleeding']

entities_list: @entity3851 :: ('MESH:D058625', 'Disease') :: ['end-stage liver failure']

entities_list: @entity2876 :: ('MESH:D001656', 'Disease') :: ['biliary atresia']

answer: @entity548 :: (MESH:D006470,Disease) :: ['bleeding']


abstract: CONTEXT: Smooth @entity11090 (SMTs) of the sinonasal tracts are very rare @entity361 , and the literature includes very limited data correlating histologic parameters with clinical outcome. As the behavior of SMTs is site-dependent, defining applicable criteria to distinguish among @entity258 , SMT of uncertain malignant potential (SMTUMP), and @entity2909 is sometimes difficult and arbitrary. OBJECTIVE: To correlate the clinicopathologic features of 12 well-differentiated sinonasal SMTs with @entity1758 index and clinical outcomes so as to better classify this group of @entity5 . DESIGN: Twelve cases of sporadic well-differentiated SMTs arising from the sinonasal tract were retrieved from both institutions. High-grade @entity1822 were excluded from this analysis. The histologic parameters assessed included circumscription, mucosal @entity1066 , cellularity, nuclear atypia, mitotic count, @entity39 , and destruction of adjacent bony structures. The histologic classification of these @entity5 was based on the guidelines for SMTs of deep soft tissues, using greater than 4 @entity6578 ( @entity6578 )/10 @entity2194 ( @entity2194 ) to separate SMTUMP from @entity1822 and the presence of 1 to 4 @entity6578 /10 @entity2194 to distinguish between @entity2909 and SMTUMP. Immunostaining of @entity1758 index was performed in 7 cases with available material. RESULTS: This study showed a 1:1.5 male-female ratio and a mean age of 40 years (range, 20-67 years). The most frequent symptoms were nasal stuffiness and/or @entity1415 . The @entity5 involved nasal cavity in 8 cases (67%), paranasal sinus alone in 2 cases (16.5%), and both nasal cavity and paranasal sinuses in 2 cases (16.5%). The @entity5 ranged in size from 0.3 to 5.5 cm (mean, 2 cm) and were classified as follows: 7 @entity2909 , 2 SMTUMPs, and 3 low-grade @entity1822 . All 7 @entity2909 , 1 SMTUMP, and 1 @entity1822 originated from vessel walls. Bone involvement was seen in both the SMTUMPs (1 of 2) and @entity1822 (2 of 3). Focal infiltrative growth was observed only in the 3 @entity1822 , 1 of which also showed microscopic @entity39 . Mitotic figures ranged from 0 to 10 (mean, 2.3), with absence of mitosis in all 7 @entity2909 , 1 to 4 @entity6578 /10 @entity2194 in the 2 SMTUMPs, and more than 4 @entity6578 /10 @entity2194 in the 3 low-grade @entity1822 . The @entity1758 index was low (<or=5%) in both @entity2909 and SMTUMP groups, while the @entity1822 showed a higher (>or=15%) proliferative index. All 12 @entity1 were treated by surgical excision, and only 1 @entity1 with @entity1822 received postoperative radiation. In all 12 @entity5 , there was neither local recurrence nor distant @entity3 after an average of 93 months of follow-up (range, 4-221 months). CONCLUSION: Well-differentiated sinonasal SMTs are rare and occur in adults with a slight female predilection. The lesions confined within the nasal cavity were more common than those involving a single paranasal sinus or both nasal cavity and paranasal sinuses. Despite variations in location, clinical manifestation, histologic features, and @entity1758 index, these @entity5 appear to follow a favorable course. Complete surgical excision appears to provide adequate treatment for these @entity1 .

title: Sinonasal smooth muscle cell XXXX : a clinicopathologic and immunohistochemical analysis of 12 cases with emphasis on the low-grade end of the spectrum.

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'patients']

entities_list: @entity2194 :: ('MESH:D005128', 'Disease') :: ['HPF', 'high-power fields']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['coagulative tumor necrosis', 'necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity1415 :: ('MESH:D004844', 'Disease') :: ['epistaxis']

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulceration']

entities_list: @entity11090 :: ('MESH:D019042', 'Disease') :: ['muscle tumors']

entities_list: @entity6578 :: ('MESH:C536987', 'Disease') :: ['MF', 'mitotic figures']

entities_list: @entity1822 :: ('MESH:D007890', 'Disease') :: ['leiomyosarcoma', 'leiomyosarcomas']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity361 :: ('MESH:C535700', 'Disease') :: ['mesenchymal neoplasms']

entities_list: @entity258 :: ('MESH:D009800', 'Disease') :: ['low-grade leiomyosarcoma']

entities_list: @entity2909 :: ('MESH:D007889', 'Disease') :: ['cellular leiomyoma', 'leiomyoma', 'leiomyomas']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumors']


abstract: We describe a 36-year-old @entity1 with advanced @entity1582 (Salmon and Durie stage III) who developed @entity1087 and severe @entity1448 after a first cure with systemic chemotherapy of @entity1891 , @entity632 , and oral @entity619 (VAD). Serology for @entity99 , B, and C and for @entity2834 was negative. A liver ultrasound and CT scan showed mild @entity382 without evidence of extrahepatic or intrahepatic biliary tree dilatation. A percutaneous liver biopsy revealed perisinusoidal deposits of an abundant slightly eosinophilic, PAS-positive amorphous substance. Immunohistochemistry showed positivity for kappa-light chains and was negative for lambda-light chains, for IgA, IgG, IgM, and IgD immunoglobulins as well as for AA and @entity1582 proteins and for amyloid P component. A diagnosis of @entity66 ( @entity66 ) of the liver was made. The @entity1 developed rapid deterioration of liver function, leading to a @entity66 and @entity204 . The occurrence of @entity66 in @entity1582 is close to 5% and @entity1582 is the underlying disease in two thirds of @entity1 with @entity66 . The kidneys are involved in almost all cases of @entity66 and @entity8 usually reveals the disease. Only three @entity1 with @entity66 of the liver without overt renal involvement have been reported so far. This is the first observation of @entity66 presenting with @entity1087 and severe @entity1448 shortly after the diagnosis of high tumor mass @entity1582 , without overt renal involvement, leading rapidly to the @entity1 's @entity204 .

title: @entity8 in a @entity1 with XXXX related to liver failure and rapid fatal outcome.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'man']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity382 :: ('MESH:D006529', 'Disease') :: ['hepatomegaly']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal dysfunction']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['multisystem dysfunction', 'light chain deposition disease', 'LCDD']

entities_list: @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'AL', 'myeloma']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity1448 :: ('MESH:D002779', 'Disease') :: ['cholestasis']

entities_list: @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine']

entities_list: @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatitis A']

answer: @entity1582 :: (MESH:D009101,Disease) :: ['multiple myeloma']


abstract: Shedding of neoplastic cells into the circulation is an essential event for the hematogenous @entity3 of solid @entity5 . Recently, several studies reported that a high frequency of @entity5 cells could be detected in the bloodstream during surgery. The intraoperative detection of hematogenous dissemination of @entity5 cells was able to identify a subset of @entity1 with @entity5 at high risk for postoperative @entity3 and to predict a poor prognosis. In order to evaluate the association between intraoperative dissemination of @entity5 cells and postsurgical survival of @entity1 with @entity1149 ( @entity1149 ), we developed a flow cytometric assay for specific detection of @entity2 cells in the blood. The monocyte-enriched population in the blood was separated by a modified Ficoll-Hypaque density centrifugation and then labeled with a combination of monoclonal antibodies specific for @entity1195 , cytokeratin (CK) and two antigens expressed on @entity2 cells (2F7 and @entity32696 ). The assay could detect quantitatively @entity2 cells (defined as @entity1195 (-1) CK(+) 2F7/S5A(+) cells), with the sensitivity limit of one @entity5 cell in 10(5) normal leukocytes. The specificity for @entity2 was 97%, which was calculated from the results of healthy subjects (20 cases) and @entity1 affected with @entity358 (26 cases) or @entity418 (14 cases). Blood samples of 31 @entity1149 @entity1 were collected from pulmonary vein during open thoracic surgery. Fifteen of them (48.4%) were found to have positive test results. The average @entity5 cell counts in these cases were 0.306 x 10(6)/l. @entity1 under 55 years of age had a significantly higher percentage of positive findings than those over 55 years of age (P < 0.05). The positive rate increased over the stages and lymph node status, but the differences were not statistically significant. Moreover, @entity1 with @entity957 at later stages (stages III and IV) had an increased frequency of positive test results than those at earlier stages (stages I and II, P < 0.05). In contrast, no such a difference was found in cases with @entity420 . On the basis of 30-months follow-up date, the median survival time and 2-year survival rate for @entity1 with positive and negative findings were 11 vs. 27 months, and 26.7 vs. 62.5%, respectively. There was a statistically significant difference between overall survival curves that favored the @entity1 with negative test results (P = 0.023). Multivariate analysis indicated the stage of disease and the positive test results as two independent factors that affected survival time (P = 0.017 and 0.027). When a comparison was made within the @entity1 at stages III and IV, the presence of @entity5 cells in blood was associated with a significantly shorter survival. These data indicate that the hematogenous dissemination of @entity2 cells during surgery would be one of the mechanisms of @entity86 @entity3 . The detection of these cells may help to identify @entity1 with poor prognosis.

title: Hematogenous dissemination of XXXX cells during surgery: quantitative detection by flow cytometry and prognostic significance.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'malignant diseases', 'tumors']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity32696 :: ('p|SUB|S|5|A', 'ProteinMutation') :: ['S5A']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['benign pulmonary diseases']

entities_list: @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal cancer']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative tumor']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

answer: @entity2 :: (MESH:D008175,Disease) :: ['lung cancer']


abstract: PURPOSE: To evaluate @entity136 - @entity900 (GC) neoadjuvant @entity900 -based chemotherapy (NAC) for pathologic response (pR) and @entity5 -specific outcomes following radical cystectomy (RC) for @entity150 and identify clinical parameters associated with pR. MATERIALS AND METHODS: We studied 150 consecutive cases of @entity150 that received GC NAC followed by open RC (2000-2013). A cohort of 121 @entity1 treated by RC alone was used for comparison. Pathologic response and @entity5 -specific survival (CSS) were compared. We created the Johns Hopkins Hospital Dose Index to characterize chemotherapeutic dosing regimens and accurately assess sufficient neoadjuvant dosing regarding @entity1 tolerance. RESULTS: No significant difference was noted in 5-year CSS between GC NAC (58%) and non-NAC cohorts (61%). The median follow-up was 19.6 months (GC NAC) and 106.5 months (non-NAC). @entity1 with residual non-muscle-invasive disease after GC NAC exhibit similar 5-year CSS relative to @entity1 with no residual @entity189 (P = 0.99). NAC pR ( <=pT1) demonstrated improved 5-year CSS rates (90.6% vs. 27.1%, P<0.01) and decreased nodal positivity rates (0% vs. 41.3%, P<0.01) when compared with nonresponders (>= pT2). Clinicopathologic outcomes were inferior in NAC pathologic nonresponders when compared with the entire RC-only-treated cohort. A lower pathologic nonresponder rate was seen in @entity1 tolerating sufficient dosing of NAC as stratified by the Johns Hopkins Hospital Dose Index (P = 0.049), congruent with the National @entity5 Network guidelines. A multivariate classification tree model demonstrated 60 years of age or younger and clinical stage @entity16065 as significant of NAC response (P< 0.05). CONCLUSIONS: Pathologic nonresponders fare worse than @entity1 proceeding directly to RC alone do. Multiple predictive models incorporating clinical, histopathologic, and molecular features are currently being developed to identify @entity1 who are most likely to benefit from GC NAC.

title: @entity136 and @entity900 neoadjuvant chemotherapy for muscle-invasive XXXX : Predicting response and assessing outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'Comprehensive Cancer']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['muscle-invasive bladder cancer']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

answer: @entity189 :: (MESH:D002277,Disease) :: ['urothelial carcinoma']


abstract: UNASSIGNED: A weak cation exchange liquid chromatography stationary phase (nylon- @entity1473 ) was prepared by grafting @entity3880 on to native @entity23552 capillary-channeled polymer (C-CP) fibers via a microwave-assisted radical polymerization. To the best of our knowledge, this is the first study of applying microwave-assisted grafting polymerization to affect nylon material for protein separation. The C-CP fiber surfaces were characterized by attenuated total reflection (ATR) infrared spectroscopy and scanning electron microscope (SEM). The anticipated @entity6738 peak at 1722.9  cm(-1) was found on the nylon- @entity1473 fibers, but was not found on the native fiber, indicating the presence of the @entity3880 on nylon fibers after grafting. The nylon- @entity1473 phase showed a    12* increase in lysozyme dynamic binding capacity (   12  mg  mL(-1)) when compared to the native fiber phase (   1  mg  mL(-1)). The loading capacity of the nylon- @entity1473 phase is nearly independent of the lysozyme loading concentration (0.05-1  mg  mL(-1)) and the mobile phase linear velocity (7.3-73  mm  s(-1)). The reproducibility of the lysozyme recovery from the nylon- @entity1473 (RSD  =  0.3%, n  =  10) and the batch-to-batch variability in the functionalization (RSD  =  3%, n  =  5) were also investigated, revealing very high levels of consistency. Fast baseline separations of myoglobin, a-chymotrypsinogen A, @entity4674 and lysozyme were achieved using the nylon- @entity1473 column. It was found that a 5* increase in the mobile phase linear velocity (7.3-to-36.5  mm  s(-1))  had little effect on the separation resolution. The microwave-assisted grafting polymerization has great potential as a generalized surface modification methodology across the applications of C-CP fibers.

title: Microwave-assisted grafting polymerization modification of XXXX capillary-channeled polymer fibers for enhanced weak cation exchange protein separations.

entities_list: @entity3880 :: ('CHEBI:51133', 'Chemical') :: ['polyacrylic acid']

entities_list: @entity6738 :: ('CHEBI:23019', 'Chemical') :: ['carbonyl']

answer: @entity23552 :: (MESH:C009916,Chemical) :: ['nylon 6']


abstract: OBJECTIVE: To explore the efficacy of anti-viral drug in combination with immunoregulatory agent in treatment of @entity6194 . METHODS: Totally 98 @entity1 with @entity6194 were divided at random into 3 groups. In groups A (42 cases) @entity16332 was used in combination with @entity36808 to treat @entity6194 . @entity16332 or @entity36808 was used alone in groups B (38 cases) and C (18 cases), respectively. The dynamic changes in serum parameters reflecting @entity97 replication and liver function were observed. RESULTS: At the end of the treatments, the rates of negative conversion of HBeA g and positive conversion of anti-HBe in the serum were significantly higher in group A than in group B (P<0.05). There was no significant difference between group A and group C (P>0.05). The rate of negative conversion of @entity97 DNA was markedly higher in group A than in group C (P<0.05). However, there was no remarkable difference between group A and group B (P>0.05). The changes in parameters of viral replication in 6 and 12 months after the treatments were not significantly different from those at the end of the treatments. The effective rate and total effective rate were markedly higher in group A than in the ther 2 groups. Meanwhile, the rate of ALT normalization of remained higher than 85% in group A. CONCLUSIONS: @entity16332 in combination with @entity36808 can exert great and lasting effects on @entity97 and is effective in normalization of ALT.

title: [Therapeutic effects of @entity16332 in combination with XXXX on @entity6194 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity16332 :: ('MESH:D019259', 'Chemical') :: ['lamivudine', 'Lamivudine']

entities_list: @entity36808 :: ('MESH:D016305', 'Chemical') :: ['thymopentin']

entities_list: @entity6194 :: ('MESH:D019694', 'Disease') :: ['chronic hepatitis B']

answer: @entity36808 :: (MESH:D016305,Chemical) :: ['Thymopentin']


abstract: BACKGROUND: @entity3458 ( @entity3458 ) is of major public health concern globally, with majority of @entity1 living in Africa. Despite its relevance, there is a dearth of research to determine the socio-demographic distribution and psychosocial impact of @entity3458 in Ghana. The objective of this study was to examine the socio-demographic distribution and psychosocial consequences of @entity3458 among @entity1 in Ghana and to assess their quality of life and coping mechanisms. METHODS: A cross-sectional research design was used that involved the completion of questionnaires on socio-demographic characteristics, quality of life, coping mechanisms, @entity148 and @entity308 . @entity1 were 387 male and female @entity1 attending a sickle cell clinic in a public hospital. RESULTS: Results showed that majority of the @entity1 were single, female, less than 39  years old and had attained secondary school level of education or less. Also, @entity1 were more satisfied by the presence of love, friends and relatives as well as home, community and neighbourhood environment. While @entity158 of varied nature and severity were the major reasons for attending hospital in @entity3458 condition, going to the hospital as well as having faith in God was the most frequently reported mechanisms for coping with an unbearable @entity3458 attacks. Results of multiple regression analysis showed that some socio-demographic and quality of life indicators had strong associations with @entity308 . CONCLUSIONS: It is recommended that a holistic intervention strategy incorporating psychosocial dimensions should be considered in the treatment and management of @entity3458 .

title: Socio-demographic characteristics and psychosocial consequences of sickle cell disease: the case of XXXX in a public hospital in Ghana.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Participants']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression', 'anxiety and/or depression']

entities_list: @entity3458 :: ('MESH:D000755', 'Disease') :: ['SCD', 'Sickle cell disease']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVES: To describe the clinical presentation, management and prognosis of @entity1 diagnosed with both primary @entity244 (pSS) and anti-neutrophil cytoplasmic antibody (ANCA)-associated @entity1333 (AAV). METHODS: French nation-wide survey completed by a systematic literature review. RESULTS: This work identified 7 new cases of coexisting pSS and @entity4700 @entity6129 ( @entity6129 ), 2 @entity2883 with @entity2883 (GPA), 2 anti-myeloperoxidase ( @entity3335 )-ANCA renal-limited AAV, and 1 eosinophilic @entity2883 with @entity2883 (EGPA). The systematic literature search identified 15 previously published cases. Among the 22 @entity1 , 19 were females. Mean age at diagnosis of AAV was 63.9  9.8years. All individuals with available information experienced at least one extra-glandular manifestation attributable to pSS. p-ANCA with anti- @entity3335 specificity were found in 76.2% (16/21), @entity7134 with anti-PR3 specificity in 14.3% (3/21) and isolated @entity7134 in 13.6% (3/22). @entity1333 involved kidneys (n=13), lungs (n=8), skin (n=6), peripheral nerves (n=5), central nervous system (n=2), small bowel (n=1), muscle (n=1), ear @entity12391 (n=1) and sinuses (n=1). The mean AAV follow-up was 73.5 (  120.0) months. While on treatment, disease remission occurred in 77.3% of cases, and one @entity204 was reported in the first 6months after diagnosis. CONCLUSION: This work shows that AAV may occur in @entity1 with pSS. These are most commonly p-ANCA associated @entity1333 with anti- @entity3335 specificity. AAV may reveal an underlying pSS or arise during its evolution, but did not precede pSS in any of these cases. AAV occurrence appears to be correlated with extra-glandular manifestations of pSS.

title: ANCA-associated vasculitis in @entity1 with primary XXXX : Detailed analysis of 7 new cases and systematic literature review.

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['Vasculitis', 'vasculitis']

entities_list: @entity6129 :: ('MESH:D055953', 'Disease') :: ['MPA', 'microscopic polyangiitis']

entities_list: @entity244 :: ('MESH:D014899', 'Disease') :: ["Sj  gren's syndrome"]

entities_list: @entity2883 :: ('MESH:D014890', 'Disease') :: ['polyangiitis', 'granulomatosis']

entities_list: @entity12391 :: ('MESH:D013991', 'Disease') :: ['chondritis']

answer: @entity244 :: (MESH:D014899,Disease) :: ['Sj  gren's syndrome']


abstract: OBJECTIVE: Screening strategies for @entity6 are controversial. Thus, we sought to determine the benefits of universal screening. @entity1 AND METHODS: Prospective study with 2121 @entity1 involved but 1610 really screened (75.9%). According to WHO's recommendations, the strategy implemented was one-step, universal screening with a 75g oral @entity413 tolerance test. Screening was performed between 24 and 28 weeks of gestation or earlier if risk factors were identified. Results were compared to previous year (2001) then only a selective screening was done. RESULTS: Application of universal screening increased the prevalence of @entity6 (8.39% to 15.65%). Out of the 252 @entity1 with gestational @entity6 , 66 did not display any identified risk factor (26.19%). Some new risk factors have been identified: age>30, Asian, Indian or Pakistan ethnies. If these new risk factors were applied, this super selective screening would have a sensibility of 96%. DISCUSSION AND CONCLUSION: Universal screening seems to be the most appropriate routine screening strategy because it is difficult to know exactly the specific risk factors of a population to do a super selective screening.

title: [Comparison of two routine screening strategies for XXXX : the experience of Jean-Verdier Hospital].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'PATIENTS']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['gestational diabetes mellitus', 'diabetes']

answer: @entity6 :: (MESH:D003920,Disease) :: ['gestational diabetes mellitus']


abstract: OBJECTIVE: To investigate the role of @entity268 -responsive element modulator-tau (CREMtau), an essential transcription factor for spermatogenesis, in ipsilateral @entity130 after unilateral testicular torsion-detorsion. DESIGN: Controlled experimental study using @entity35 . SETTING: Research laboratory. ANIMAL(S): Twenty adult male @entity35 . INTERVENTION(S): Ten @entity35 in the control group underwent a sham operation of the left testes. Ten @entity35 in the torsion-detorsion group received 1 hour of @entity4115 . Orchiectomy was performed on all @entity35 3 months after detorsion. MAIN OUTCOME MEASURE(S): Testicular spermatogenesis was evaluated by measuring testicular weight, mean seminiferous tubular diameter, number of germ cell layers, and mean testicular biopsy score. The expressions of CREMtau mRNA and protein in testes were detected by reverse transcription-polymerase chain reaction and Western blot, respectively. RESULT(S): Unilateral testicular torsion-detorsion caused significant spermatogenic @entity16 , including reductions in testicular weight, mean seminiferous tubular diameter, number of germ cell layers, and mean testicular biopsy score. In ipsilateral testes with @entity16 , the expressions of CREMtau mRNA and protein were also significantly reduced. CONCLUSION(S): Reduction in testicular CREMtau expression may be one of the mechanisms responsible for impairment of spermatogenesis in ipsilateral testes after unilateral testicular torsion-detorsion.

title: Role of @entity268 -responsive element modulator-tau (CREMtau) in ipsilateral XXXX after unilateral testicular torsion-detorsion.

entities_list: @entity4115 :: ('MESH:D013086', 'Disease') :: ['left testicular torsion']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['spermatogenic damage', 'damage in the ipsilateral testes']

entities_list: @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats', 'rats']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['testicular injury']

answer: @entity130 :: (MESH:D014947,Disease) :: ['testicular injury']


abstract: BACKGROUND: We compared results of genotyping of @entity1534 @entity2757 and vacA virulence genes in DNA from gastric biopsies, both @entity982 -embedded and frozen, and from stool samples, in order to evaluate the comparative sensitivity of the stool assay. METHODS: Genomic DNA from @entity982 -embedded biopsies, unfixed frozen biopsies, and stool samples of the same 20 @entity1 was amplified for the @entity2757 gene, an empty site (which provides a positive signal for @entity2757 negative strains) and for the s and m alleles of the vacA gene. Composite genotypes were determined by combining data from analysis of all three materials. RESULTS: Analysis of none of the materials taken singly showed all of the genotypes revealed by all three materials taken together, probably because of sampling error. Analysis of @entity982 biopsies revealed 83.5%, that of frozen biopsies revealed 74.7% and that of stools revealed 75.9% of the genotypes. There was no significant difference in the percentage of the @entity1534 genotypes identified from the three materials. Analysis of combinations of frozen biopsies and stools revealed 89.9% of the composite genotypes, and that of @entity982 biopsies and stools revealed 96.2% of the composite genotypes. Evidence of multiple genotypes was found in 10 of 20 (50%) of the cases. CONCLUSIONS: Any one of the investigated biological materials can be used for detection of @entity2757 and vacA genes, but no single assay provided a complete genotype. The use of a combination of two materials may generate a more accurate representation of @entity1534 genotypes in each individual.

title: Comparison of genotyping of @entity1534 XXXX and vacA virulence genes from gastric biopsies and stool specimens.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin']

entities_list: @entity1534 :: ('210', 'Species') :: ['H. pylori', 'Helicobacter pylori']

answer: @entity2757 :: (6279,Gene) :: ['cagA']


abstract: OBJECTIVE: To describe the functional gain (FGain) with pediatric @entity1566 inpatient rehabilitation and to identify the relationship of various factors to FGain in pediatric @entity1566 inpatient rehabilitation. DESIGN: Retrospective chart review of a series of 91 @entity1 with @entity1566 admitted from 1993 to 1998 in a freestanding rehabilitation hospital. Admission and discharge functional status were assessed with the Pediatric Functional Independence Measure (WeeFIM) instrument for @entity1 <or=7 yr and the Adult Functional Independence Measure (FIM) instrument for @entity1 >7 yr. The outcome measure is the FGain (difference between the discharge and admission functional status). RESULTS: Significant gains in functional status were observed in all @entity1 . FGain was not significantly related to age, sex, length of inpatient rehabilitation, pathogenesis, or @entity1939 or neurologic level of injury. However, there was a trend for higher FGain for @entity1 with incomplete @entity1566 and traumatic @entity1566 . CONCLUSIONS: Functional improvement occurs with pediatric @entity1566 inpatient rehabilitation. There is a trend for higher FGain in @entity1 with less severe @entity130 . The lack of relationship between FGain and length of inpatient rehabilitation suggests that a variety of other factors influence the relationship between FGain and length of inpatient rehabilitation.

title: Functional improvement after pediatric XXXX .

entities_list: @entity1566 :: ('MESH:D013119', 'Disease') :: ['spinal cord injury']

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity1939 :: ('MESH:D001766', 'Disease') :: ['completeness']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['injury and traumatic injury']

answer: @entity1566 :: (MESH:D013119,Disease) :: ['spinal cord injury']


abstract: BACKGROUND: @entity46924 is a @entity8142 agonist, a new class of drugs used to treat type 2 @entity6 . We did a prospective meta-analysis of the cardiovascular safety of @entity46924 as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for @entity6 . METHODS: We did a meta-analysis of eight phase 3 trials and one phase 2b trial in which @entity1 were randomly assigned to @entity46924 , placebo, or active comparators ( @entity16024 , insulin glargine, insulin lispro, liraglutide, @entity12098 , or @entity12350 ). The safety population included 5107 @entity1 , of whom 2524 took @entity46924 (4870 @entity1 -years) and 2583 took comparators (5213 @entity1 -years). Possible major cardiovascular events were recorded prospectively and adjudicated by an independent endpoint committee masked to treatment allocation. The primary endpoint was a composite of first occurrence of major adverse cardiovascular events (ie, @entity65 , non-fatal @entity583 , or @entity64 ) or hospital admission for unstable @entity951 . Secondary endpoints were major adverse cardiovascular events alone, all-cause mortality, silent @entity583 , hospital admission for @entity712 , @entity662 , other @entity951 , and subdural or extradural @entity548 . The occurrence of all other adverse events classified by the investigators as cardiovascular events were documented, but these were not adjudicated. FINDINGS: The primary endpoint was not significantly different between @entity46924 and all comparators (58 events vs 58 events; hazard ratio [HR] 1  00, 95% CI 0  68-1  49, p=0  0019 for non-inferiority). Major adverse cardiovascular event alone was also not significantly different (52 events vs 53; HR, 0  99; 95% CI, 0  65-1  49). When @entity46924 was compared separately with placebo or active comparators, we noted no significant differences. We detected no significant differences in the other secondary endpoints. More @entity1 had @entity955 or @entity956 in the @entity46924 group (35 [1  4%] of 2524 @entity1 ; 8  6 events per 1000 @entity1 -years) than in the all-comparators group (16 [0  6%] of 2583 @entity1 ; 3  4 events per 1000 @entity1 -years). INTERPRETATION: Cardiovascular events were not significantly more likely to occur with @entity46924 than with all comparators. Because the upper bound of the 95% CI for major adverse cardiovascular event plus hospital admission for unstable @entity951 was greater than 1  3, a dedicated study with a cardiovascular endpoint is underway to confirm the safety of @entity46924 . FUNDING: GlaxoSmithKline.

title: Cardiovascular safety of XXXX in the Harmony programme: a meta-analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'person']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['non-fatal stroke']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity16024 :: ('MESH:C057619', 'Chemical') :: ['glimepiride']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhage']

entities_list: @entity12098 :: ('MESH:C060836', 'Chemical') :: ['pioglitazone']

entities_list: @entity46924 :: ('MESH:C534611', 'Chemical') :: ['Albiglutide', 'albiglutide']

entities_list: @entity12350 :: ('MESH:C496398', 'Chemical') :: ['sitagliptin']

entities_list: @entity956 :: ('MESH:D001282', 'Disease') :: ['atrial flutter']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

entities_list: @entity8142 :: ('2740', 'Gene') :: ['glucagon-like peptide-1 receptor']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular death']

answer: @entity46924 :: (MESH:C534611,Chemical) :: ['albiglutide']


abstract: Chemically induced long-term potentiation (cLTP) could potentially work by directly stimulating the biochemical machinery that underlies synaptic plasticity, bypassing the need for synaptic activation. Previous reports suggested that agents that raise @entity268 concentration might have this capability. We examined the cLTP induced in acute slices by application of Sp-cAMPS or a combination of the adenylyl cyclase activator, @entity1928 , and the phosphodiesterase inhibitor, @entity7428 . Under our conditions, cLTP was induced but only if inhibition was reduced. We found that this form of cLTP was blocked by a @entity1024 receptor (NMDAR) antagonist and required the low-frequency test stimulation typically used to monitor the strength of synapses. Interestingly, similar LTP could be induced by lowering the @entity1025 concentration of the ACSF during @entity1928 / @entity7428 or Sp-cAMPS application or even by just lowering @entity1025 concentration alone. This LTP was also NMDAR dependent and required only a few ( approximately 5) low-frequency stimuli for its induction. The finding that even low-frequency synaptic stimulation was sufficient for LTP induction indicates that a highly sensitized plasticity state was generated. The fact that some stimulation was required means that potentiation is probably restricted to the stimulated axons, limiting the usefulness of this form of cLTP. However, when similar experiments were conducted using slice cultures, potentiation occurred without test stimuli, probably because the @entity7624 connections are extensive and because presynaptic spontaneous activity is sufficient to fulfill the activity requirement. As in acute slices, the potentiation was blocked by an NMDAR antagonist. Our general conclusion is that the induction of LTP caused by elevating @entity268 requires presynaptic activity and @entity143 channel opening. The method of inducing cLTP in slice cultures will be useful when it is desirable to produce NMDAR-dependent LTP in a large fraction of synapses.

title: XXXX -induced LTP in the CA1 hippocampal region is @entity143 receptor dependent.

entities_list: @entity1024 :: ('CHEBI:31882', 'Chemical') :: ['N-methyl-d-aspartate']

entities_list: @entity7428 :: ('MESH:D020889', 'Chemical') :: ['rolipram']

entities_list: @entity1928 :: ('MESH:D005576', 'Chemical') :: ['forskolin']

answer: @entity1928 :: (MESH:D005576,Chemical) :: ['Forskolin']


abstract: AIMS: We examined the effectiveness of the Japanese @entity6 Risk Score (JPDRISC) and fatty liver markers for predicting incident @entity6 . METHODS: We created the JPDRISC. The study periods I and II were January 2007 to May 2009 and June 2009 to December 2011, respectively. A total of 2084 @entity1 (1389 @entity1 , 695 @entity1 ; mean age: 46 years) were included. @entity1 with @entity6 in the Period I and those with @entity1068 intake >140g/week were excluded. A total of 1515 @entity1 were included. @entity1560 using ultrasonography scores (FLUS) were assigned. RESULTS: The mean observation period was 26.3 months, and 24 @entity1 had developed @entity6 between the Periods I and II. In logistic regression analysis, the JPDRISC (OR=1.197, 95% C.I.: 1.062-1.350, p=0.003) and FLUS (OR=2.591, 95% C.I.: 1.411-4.758, p=0.002) in the Period I were independent determinants of incident @entity6 . In receiver operating characteristic analysis, sensitivity and specificity for incident @entity6 were 0.885 and 0.536, respectively, in @entity1 with both FLUS>= 1 and the total JPDRISC>= 6 in the Period I. The sensitivity was better than the JPDRISC alone (sensitivity 0.696) and FLUS alone (sensitivity 0.750). CONCLUSIONS: JPDRISC and FLUS were independently associated with incident @entity6 and their combination is useful.

title: Analysis of the Japanese @entity6 Risk Score and fatty liver markers for incident XXXX in a Japanese cohort.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'people', 'People', 'men']

entities_list: @entity1560 :: ('MESH:D005234', 'Disease') :: ['Fatty liver']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: BACKGROUND: The relationship between major discharge diagnoses and prediction of in-hospital @entity204 has been intensively studied. The relation between the presenting complaint at the @entity341 ( @entity341 ) and in-hospital fatality, however, is less well known. OBJECTIVE: To investigate if presenting complaints add information regarding in-hospital fatality risk for nonsurgical @entity341 @entity1 . METHODS: Investigating the relationship of in-hospital fatality rate and presenting complaint by comparing the presenting complaints, discharge diagnoses and in-hospital fatality for all nonsurgical @entity1 visiting the @entity341 during 1 year. RESULTS: Of 12,995 nonsurgical admissions, 40% were treated as in-hospital @entity1 . Among these, 328 in-hospital deaths occurred. Age was the most powerful predictor of @entity204 in hospitalized @entity1 (P<0.0001). After adjustment for age, the female sex was found to be protective [odds ratio (OR) 0.73, 95% confidence interval (CI) 0.58-0.92, P=0.007)]. Compared with the largest complaint group, @entity662 with an in-hospital fatality rate of 2.5%, there was a significantly increased risk of dying among those with @entity64 -like symptoms (OR 2.04, 95% CI 1.35-3.08, P=0.0007), dyspnoea (OR 1.95, 95% CI 1.27-3.00, P=0.002) or general disability (OR 1.81, 95% CI 1.17-2.79, P=0.008). CONCLUSIONS: The presenting complaint at the @entity341 carries valuable information of the risk for in-hospital fatality in nonsurgical @entity1 . This knowledge can be valuable in the prioritization between different @entity1 groups in the process of initiating diagnostics and treatment procedures at the @entity341 .

title: The XXXX presenting complaint as predictor of in-hospital fatality.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity341 :: ('MESH:D004630', 'Disease') :: ['ED', 'Emergency Department']

answer: @entity341 :: (MESH:D004630,Disease) :: ['Emergency Department']


abstract: OBJECTIVE: We analyze the incidence of postoperative severe airflow limitation after single-stage unifocalization in @entity1 with @entity1146 , @entity1757 , and major aortopulmonary collateral arteries (PA/ @entity1757 /MAPCAs) and comment on the treatment performed. METHODS: From 1994 until 2014, 118 @entity1 with diagnosis of PA, @entity1757 , MAPCAs underwent surgical treatment. Four @entity1 (3.4%) developed severe airflow complications postoperatively. Chromosome 22q11 deletion was present in three of them. Median age at the time of unifocalization was 6.2 months (range 21 days to 11 months). RESULTS: The first @entity1 developed malacia and compression of the left bronchus from the distal RV-PA conduit and was treated with external bronchial stenting with two @entity1844 rings. The second @entity1 developed recurrent @entity292 treated with multiple surgical esophageal and bronchus reconstructions. The third @entity1 presented with bilateral @entity2488 treated with bilateral stenting followed by surgical elongation of the neo-left pulmonary artery to avoid external compression. The last @entity1 developed @entity17593 treated with bilateral bronchial stenting followed by RV-PA conduit replacement and endobronchial stenting calibration. CONCLUSION: Particular categories of @entity1 with PA, @entity1757 , MAPCAs (22q11 chromosome deletion, neonates/ @entity1 , @entity1 with dominant/exclusive collaterals) may be more predisposed to develop airway compromise. The treatment of the lesion should be individualized according to the pathogenic mechanism. We suggest endoluminal treatment in absence of compression by vascular structures while surgery was used in case of extrinsic compression.

title: Airway Complications After Single-Stage Unifocalization for @entity1146 , XXXX , and Major Aortopulmonary Collateral Arteries.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'infants', 'child']

entities_list: @entity1844 :: ('MESH:D002357', 'Disease') :: ['incomplete costal cartilage']

entities_list: @entity2488 :: ('MESH:D001982', 'Disease') :: ['bronchial malacia']

entities_list: @entity1757 :: ('MESH:D006345', 'Disease') :: ['VSD', 'ventricular septal defect']

entities_list: @entity17593 :: ('MESH:D055091', 'Disease') :: ['bilateral bronchomalacia']

entities_list: @entity292 :: ('MESH:D005402', 'Disease') :: ['esophagus-left bronchus fistula']

entities_list: @entity1146 :: ('MESH:D018633', 'Disease') :: ['pulmonary atresia']

answer: @entity1757 :: (MESH:D006345,Disease) :: ['Ventricular Septal Defect']


abstract: PURPOSE: This study investigated the effects of irrigation solutions, administered at either 21 or 37    C in percutaneous nephrolithotomy (PCNL), on @entity2332 and related @entity260 such as late emergence and late recovery from anesthesia, shivering, @entity8193 , and excess @entity548 . METHODS: Sixty @entity1 who were scheduled for PCNL were enrolled in this prospective randomized double-blind study. Irrigation solutions at room temperature were administered to @entity1 in group R (30 @entity1 ), and warmed irrigation solutions were administered to @entity1 in group W (30 @entity1 ). The two groups were compared for core and peripheral body temperature, incidence of @entity2332 , duration of emergence from anesthesia, duration of recovery from anesthesia, shivering, @entity8193 , and hemoglobin levels. RESULTS: @entity2332 was incident in 19  @entity1 (63.3  %) in group W and in 27 @entity1 (90  %) in group R at the end of surgery. The difference between the initial and the final core body temperature was 0.9      0.6    C group W and 1.4      0.7    C in group R (p  =  0.003). The extubation time was 4.4      2.2  min in group W and 5.9      3  min in group R (p  =  0.032). Shivering was detected in seven @entity1 (23.3  %) in group W and in 15  @entity1 (50  %) in group R (p  =  0.032). The recovery duration was 49.8      24.6  min in group W and 67.6      33.9  min in group R (p  =  0.023). CONCLUSIONS: Administration of irrigation solutions at room temperature in PCNL operations causes the body temperature to decrease significantly, which results in @entity260 such as late emergence from anesthesia, late recovery from anesthesia, and shivering.

title: A prospective randomized double-blind study on the effects of the temperature of irrigation solutions on thermoregulation and XXXX in percutaneous nephrolithotomy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications']

entities_list: @entity8193 :: ('MESH:D000140', 'Disease') :: ['lactic acidosis']

entities_list: @entity2332 :: ('MESH:D007035', 'Disease') :: ['hypothermia', 'Hypothermia']

answer: @entity260 :: (MESH:D011183,Disease) :: ['postoperative complications']